Immunome presents preclinical data for IM-1021, ADC payload HC74

Immunome (IMNM) recently presented preclinical data for IM-1021 and the associated proprietary ADC payload HC74. The results were presented in a poster entitled “Preclinical evaluation of IM-1021, a ROR1-targeted antibody-drug conjugate with a novel topoisomerase I linker payload” at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona on October 24. The poster included preclinical results for IM-1021 in both liquid and solid tumors while also highlighting the enhanced ADME properties of HC74: IM-1021 showed superior efficacy compared to zilovertamab vedotin in both the Jeko-1 mantle cell lymphoma model and the MDA-MB-468 triple negative breast cancer model. In the MDA-MB-468 study, 5 out of 8 animals achieved complete responses after three 5 mg/kg doses. HC74 demonstrated superior potency compared to deruxtecan in a panel of 89 cancer cell lines. HC74 showed faster hepatocyte clearance, higher permeability, and lower efflux than deruxtecan. When evaluated in doxorubicin-resistant and vincristine-resistant cell lines, HC74 showed no reduction in potency compared to the parental NCI-H69 cell line. Immunome expects to submit an IND for the IM-1021 program to the FDA in the first quarter of 2025.